Abstract

BackgroundThe p66ShcA redox protein is the longest isoform of the Shc1 gene and is variably expressed in breast cancers. In response to a variety of stress stimuli, p66ShcA becomes phosphorylated on serine 36, which allows it to translocate from the cytoplasm to the mitochondria where it stimulates the formation of reactive oxygen species (ROS). Conflicting studies suggest both pro- and anti-tumorigenic functions for p66ShcA, which prompted us to examine the contribution of tumor cell-intrinsic functions of p66ShcA during breast cancer metastasis.MethodsWe tested whether p66ShcA impacts the lung-metastatic ability of breast cancer cells. Breast cancer cells characteristic of the ErbB2+/luminal (NIC) or basal (4T1) subtypes were engineered to overexpress p66ShcA. In addition, lung-metastatic 4T1 variants (4T1-537) were engineered to lack endogenous p66ShcA via Crispr/Cas9 genomic editing. p66ShcA null cells were then reconstituted with wild-type p66ShcA or a mutant (S36A) that cannot translocate to the mitochondria, thereby lacking the ability to stimulate mitochondrial-dependent ROS production. These cells were tested for their ability to form spontaneous metastases from the primary site or seed and colonize the lung in experimental (tail vein) metastasis assays. These cells were further characterized with respect to their migration rates, focal adhesion dynamics, and resistance to anoikis in vitro. Finally, their ability to survive in circulation and seed the lungs of mice was assessed in vivo.ResultsWe show that p66ShcA increases the lung-metastatic potential of breast cancer cells by augmenting their ability to navigate each stage of the metastatic cascade. A non-phosphorylatable p66ShcA-S36A mutant, which cannot translocate to the mitochondria, still potentiated breast cancer cell migration, lung colonization, and growth of secondary lung metastases. However, breast cancer cell survival in the circulation uniquely required an intact p66ShcA S36 phosphorylation site.ConclusionThis study provides the first evidence that both mitochondrial and non-mitochondrial p66ShcA pools collaborate in breast cancer cells to promote their maximal metastatic fitness.

Highlights

  • The p66ShcA redox protein is the longest isoform of the Shc1 gene and is variably expressed in breast cancers

  • We examined whether wild-type p66ShcA or the S36A mutant differed in their ability to stimulate mitochondrial-dependent reactive oxygen species (ROS) production in 4T1-537 breast cancer cells using MitoSOX flow cytometric analysis

  • Non-mitochondrial p66ShcA pools enhance breast cancer cell migration by promoting adhesion dynamics Ruling out an epithelial-to-mesenchymal transition (EMT) as the primary mechanism by which p66ShcA increased breast cancer lung metastasis, we examined its impact on the migratory properties of breast cancer cells

Read more

Summary

Introduction

The p66ShcA redox protein is the longest isoform of the Shc gene and is variably expressed in breast cancers. In response to a variety of stress stimuli, p66ShcA becomes phosphorylated on serine 36, which allows it to translocate from the cytoplasm to the mitochondria where it stimulates the formation of reactive oxygen species (ROS). Conflicting studies suggest both pro- and anti-tumorigenic functions for p66ShcA, which prompted us to examine the contribution of tumor cell-intrinsic functions of p66ShcA during breast cancer metastasis. Whereas p46/p52ShcA transduce mitogenic signals [4, 5], p66ShcA induces oxidative stress by facilitating mitochondrial-dependent reactive oxygen species (ROS) production [7]. P66ShcA stimulates ROS production by binding to cytochrome c and facilitating the transfer of electrons from cytochrome c to molecular oxygen [10]

Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call